Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events-Reply

JAMA. 2018 Mar 27;319(12):1279-1280. doi: 10.1001/jama.2018.0195.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Algorithms
  • Anticoagulants
  • Cytochrome P-450 CYP2C9 / genetics
  • Genotype
  • Humans
  • International Normalized Ratio*
  • Pharmacogenetics
  • Warfarin*

Substances

  • Anticoagulants
  • Warfarin
  • Cytochrome P-450 CYP2C9